Denosumab for the prevention of osteoporotic fractures in postmenopausal women

  • Technology appraisal guidance
  • TA204
  • Published: 
Download guidance (PDF)

7 Review of guidance

7.1 The guidance on this technology will be considered for review at the same time that NICE technology appraisal guidance 160 and 161 (2008; amended 2010) are considered for review. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
October 2010